IMMUNE Partners With Patient Community Group LYFEBULB

By GlobeNewswire,  June 25, 2014, 02:30:00 AM EDT


Lyfebulb Social Club's Third Event Focuses on Personalized Therapies in Crohn's Disease and Ulcerative Colitis

NEW YORK, June 25, 2014 (GLOBE NEWSWIRE) -- Lyfebulb, an organization dedicated to helping people achieve their optimal lifestyle by addressing general and chronic health concerns, and Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) co-hosted the third Lyfebulb event on June 19th at Brasserie Ruhlmann in New York. The event provided an opportunity for guests to connect and learn about emerging and personalized therapies in Crohn's and Colitis Disease, also known as Inflammatory Bowel Disease (IBD). The event's host committee included Lyfebulb founder and renowned health and wellness expert, Dr. Karin Hehenberger, Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, and Dr. James Aisenberg, distinguished gastroenterologist and Associate Clinical Professor of Medicine at The Mount Sinai Hospital.

From left to right: Dr. Neville Bamji, Dr. Karin Hehenberger, Dr. Daniel Teper and Michael Fensterstock




A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=26132

"The Lyfebulb Social Club was created to bring patients together to share their experiences and to introduce them to latest developments that will help them lead better lives," says Dr. Karin Hehenberger, Founder of Lyfebulb. "We are thrilled to have the innovative company, Immune Pharmaceuticals, and noted gastroenterologist, Dr. Bamji, join us for our first event focused on Crohn's & Colitis and to provide our members with a first glimpse of new therapies in development."

Dr. Neville Bamji, board-certified gastroenterologist and Clinical Instructor of Medicine at The Mount Sinai Hospital, shared insights on the limitation of currently available treatment options and the need for more targeted and personalized therapies to help manage the diseases. Acting as patient representative, Michael Fensterstock made a stirring appearance by discussing his personal account of living with inflammatory bowel disease with guests, including the struggles and the successes.

"Lyfebulb is an exceptional organization, which we are thrilled to partner with for this event," said Immune Pharmaceuticals CEO Dr. Daniel Teper. "At Immune Pharmaceuticals, our work is aimed at improving the lives of those with inflammatory and chronic diseases and the mission of Lyfebulb closely aligns with our goals. We hope in working together to introduce new personalized solutions for individuals struggling with chronic conditions such as Crohn's Disease and Ulcerative Colitis."

IBD affects over 3 million individuals in the United States and Europe, striking both men and women equally. The symptoms of IBD range from mild to severe, including chronic belly pain, immense discomfort and disruptions to a regular body routine, and may come and go over time. Depending on severity, complications from IBD may require hospitalization, surgery, or use of a colonoscopy bag. 

The Lyfebulb Social Club hosts monthly events to connect individuals with chronic disease in a positive, interactive environment. Each event highlights a chronic illness and offers members a space to freely discuss their conditions. The Social Club features guest speakers, patient representatives, new products, as well as many other useful ideas for anyone living with a chronic condition. To become a member and hear about upcoming events, visit http://www.lyfebulb.com/profile.

About Lyfebulb

Lyfebulb was founded in 2014 by Dr. Karin Hehenberger M.D., Ph.D., T1D, with a mission to help those living with a chronic disease lead their optimal lifestyle. Through an online platform and offline events, Lyfebulb connects, educates, and inspires individuals living with chronic illnesses. The LyfeBulb Social Club is a monthly series that brings together thought leaders, patients, experts and renowned professionals in an informative and relaxed environment. 

For more information, please visit www.lyfebulb.com.

About Dr. Karin Hehenberger

Dr. Hehenberger is a health and wellness expert, with over 15 years experience in the healthcare industry, ranging from executive positions with JNJ, JDRF, Eyetech, and most recently Coronado Biosciences, to partnership roles at private and public investments firms. Dr. Hehenberger trained as an MD and Ph.D. at the Karolinska Institute, Sweden, and did her post-doctoral fellowship at the Joslin Diabetes Center, Harvard Medical School. She is the founder and CEO of Lyfebulb, and also on the executive team at Immune Pharmaceuticals as Senior Vice President, Medical Affairs and Corporate Communications, responsible for the company's external communications and relationships with key opinion leaders, patient advocacy groups, media and investors.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's Disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Bertilimumab is a personalized treatment for auto-immune diseases with patient selection based on a companion diagnostic test. Immune's pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, Crolibulin, a small molecule in Phase II in collaboration with the National Cancer Institute and Amiket™, a Neuropathic Pain drug candidate ready for Phase III. Amiket has received Orphan Drug Designation for Post Herpetic Neuralgia.

For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that we will not be able to find a partner to help conduct the Phase 3 trials for AmiKet™ on attractive terms, a timely basis or at all the risk that we will not obtain approval to market and commercialize any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with our ability to protect our intellectual property; risks associate with our ability to raise additional funds; and our liquidity. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT:  LYFEBULB
          WWW.LYFEBULB.COM

          RUBENSTEIN PUBLIC RELATIONS
          SHAY PANTANO 212-843-8062
          SPANTANO@RUBENSTEINPR.COM
Source: Immune Pharmaceuticals Inc.

This article appears in: News Headlines

Referenced Stocks: IMNP


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
FTR $ 6.725 0.79 ▲ 13.22%
WIN $ 11.995 1.47 ▲ 13.91%
SIRI $ 3.43 0.05 ▲ 1.48%
T $ 36.685 1.04 ▲ 2.90%
CTL $ 40.50 2.79 ▲ 7.40%
RAD $ 6.64 0.05 ▼ 0.75%
AAPL $ 98.97 0.05 ▼ 0.05%
FB $ 74.295 0.63 ▼ 0.83%

As of 7/29/2014, 02:13 PM